Showing posts with label ATAC. Show all posts
Showing posts with label ATAC. Show all posts
Sunday, March 06, 2011
10-year analysis of the ATAC trial: wrong conclusion? : The Lancet Oncology
"The 10-year analysis of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial1 continues to show a difference in its primary endpoint of disease-free survival, which favours anastrozole as adjuvant treatment for postmenopausal women with hormone-responsive breast cancer. Ultimately, however, clinical trials have two aims: either to show improvement in survival, or in its quality.
Anastrozole has failed to meet these criteria when compared with tamoxifen."
add your opinions
anastrozole
,
arimidex
,
ATAC
,
breast cancer
,
overall survival
,
quality
,
Tamoxifen
Subscribe to:
Posts
(
Atom
)